Shield Therapeutics plc confirmed that, in line with prior guidance, it will launch Accrufer® in the US on July 1, 2021. Launch stocks of Accrufer® are currently being distributed through the wholesaler channels and will be available to doctors and other prescribers in all parts of the US by July 1, 2021. A sales force including 30 sales representatives has been recruited and trained and will be starting to contact key prescribers during next week.